Drug Trial Radar · NCT07154511
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Nov 7, 2025
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Prabesh KanelAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Farmer Family Foundation
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation. The main questions it aims to answer are: 1. Does tributyrin improve memory/thinking test scores and walking/balance ability? 2. What medical problems do participants have when taking tributyrin? Researchers will compare tributyrin to a placebo (a look-alike substance that contains no drug) to see if tributyrin works to treat Parkinson disease symptoms. Participants will: 1. Take tributyrin 3 times a day for 80-100 days 2. Complete motor and cognitive testing at the clinic before and after the supplementation period 3. Complete brain imaging (MRI scans and PET scans) before and after the supplementation period.
Conditions
- Parkinson Disease
- Parkinson Disease Dementia
Interventions
TributyrinDrug
Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.
PlaceboDrug
Participants will take 500mg TID placebo for 90 days +/- 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Single composite global cognitive z-scoreTime frame: Baseline and post-intervention (83-97 days after starting supplement)
- Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III ScoreTime frame: Baseline and post-intervention (83-97 days after starting supplement)
- Safety and tolerability of tributyrinTime frame: During and after 83-97 day supplementation period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Domino's Farms
Ann Arbor, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.